Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden hormone link in stubborn high blood pressure revealed

NCT ID NCT06829537

Knowledge-focused Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 1,100 adults in the US whose high blood pressure stays high despite taking multiple medications. Researchers checked if these people also have a hormone condition called endogenous hypercortisolism, where the body makes too much cortisol. Participants gave blood and urine samples and some had a CT scan. The goal was simply to find out how common this hormone problem is in this group, not to test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,143 people

The number who actually took part.

Started

Mar 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Office-based care and university clinics in the United States.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Each patient must meet all of the following criteria to be enrolled in the study: * Signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study-specific screening procedures. * Male/female patients must be 18 years or older at the time of signing the informed consent. * Meet either of the following criteria: * Has rHTN, defined by the American Heart Association as BP above target (systolic ≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes at their maximally tolerated doses, and 1 of these agents is a diuretic. * Or, has rHTN, defined by the American Heart Association as SBP at target or above target requiring concurrent use of 4 or more antihypertensive medications of different classes. Exclusion Criteria: * Patients who meet any of the following criteria will not be permitted entry to the study: * White coat hypertension, ie, elevated BP in the office only, as determined by the Investigator. * Non-adherence to BP medications, as determined by the Investigator. * Systemic glucocorticoid medications exposure (excluding inhalers or topical) within 3 months of screening. For temporary exposures to oral glucocorticoids the Medical Monitor may be consulted to determine eligibility. * Has an historical estimated glomerular filtration rate (eGFR) \< 30. * Has severe untreated sleep apnea as determined by the Investigator. * Has excessive alcohol consumption (eg, \> 14 units/week for male, \> 7 units/week for female) as determined by the Investigator. * Has severe acute psychiatric, medical, or surgical illness, as determined by the Investigator. * Is a woman who is pregnant or lactating. For women of childbearing potential, a urine pregnancy test must be negative before doing the DST. A woman of childbearing potential includes women \< 50 years old, women whose surgical sterilization was performed \< 6 months ago, and women who have had a menstrual period in the last 12 months. * Is a woman who is on oral contraceptive pills (OCPs). Women on OCPs may be screened but must be willing and able to stop OCPs for at least 6 weeks prior to screening assessments. OCPs can be resumed immediately after the blood draw for the DST. * Has history of congenital adrenal hyperplasia. * Has had the diagnosis of Cushing syndrome and/or has used or plans to use any of the following treatments for Cushing syndrome: • Mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, lanreotide, pasireotide, longacting octreotide or pasireotide. * Is unable to take dexamethasone due to a history of hypersensitivity or severe reaction to dexamethasone. * Is a staff member working directly on the study or is a family member of someone working directly on the study, including any of the Sponsor's employees, the Investigator or the site staff.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypercortisolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cushing syndrome resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypercortisolism Resistant hypertension

Contacts and locations

Locations

  • Site 009

    Atlanta, Georgia, 30303, United States

  • Site 041

    Los Angeles, California, 90048, United States

  • Site 042

    Cleveland, Ohio, 44195, United States

  • Site 046

    Covington, Kentucky, 41011, United States

  • Site 059

    Wilmington, North Carolina, 28401, United States

  • Site 061

    Metairie, Louisiana, 70006, United States

  • Site 067

    Boston, Massachusetts, 02115, United States

  • Site 070

    Albany, New York, 12203, United States

  • Site 168

    Charleston, South Carolina, 29425, United States

  • Site 181

    Chapel Hill, North Carolina, 27514, United States

  • Site 195

    Columbus, Ohio, 43201, United States

  • Site 369

    San Antonio, Texas, 78229, United States

  • Site 370

    Dallas, Texas, 75230, United States

  • Site 371

    Las Vegas, Nevada, 89148, United States

  • Site 375

    Torrance, California, 90502, United States

  • Site 377

    New Orleans, Louisiana, 70112, United States

  • Site 378

    Huntington Park, California, 90255, United States

  • Site 379

    Redondo Beach, California, 90247, United States

  • Site 387

    Tarzana, California, 91356, United States

  • Site 394

    Olney, Maryland, 20832, United States

  • Site 406

    La Jolla, California, 92037, United States

  • Site 408

    Lufkin, Texas, 75904, United States

  • Site 410

    Baltimore, Maryland, 21239, United States

  • Site 436

    Cincinnati, Ohio, 45219, United States

  • Site 440

    Rockville, Maryland, 20854, United States

  • Site 444

    Edgewater, Florida, 32132, United States

  • Site 456

    Austin, Texas, 78759, United States

  • Site 524

    New York, New York, 10029, United States

  • Site 525

    Miami, Florida, 33155, United States

  • Site 526

    Houston, Texas, 77054, United States

  • Site 527

    Miami, Florida, 33173, United States

  • Site 528

    Maitland, Florida, 32751, United States

  • Site 529

    Mooresville, North Carolina, 28117, United States

  • Site 530

    Troy, Michigan, 48085, United States

  • Site 531

    Weslaco, Texas, 78596, United States

  • Site 532

    Winfield, Illinois, 60190, United States

  • Site 533

    Torrance, California, 90505, United States

  • Site 534

    Mt. Pleasant, South Carolina, 29464, United States

  • Site 535

    Northridge, California, 91324, United States

  • Site 536

    Durham, North Carolina, 27701, United States

  • Site 537

    Port Charlotte, Florida, 33952, United States

  • Site 538

    La Jolla, California, 92037, United States

  • Site 540

    Morrisville, North Carolina, 27560, United States

  • Site 541

    Reno, Nevada, 89502, United States

  • Site 542

    Santa Maria, California, 93454, United States

  • Site 551

    Cleveland, Ohio, 44109, United States

  • Site 552

    Chicago, Illinois, 60607, United States

  • Site 553

    Cooper City, Florida, 33024, United States

  • Site 554

    Miami, Florida, 33126, United States

  • Site 555

    Greenville, North Carolina, 27834, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.